MyoKardia, Inc. (NASDAQ: MYOK) today announced that it has dosed the first subjects in a Phase 1 clinical study of MYK-224, a small molecule candidate being developed for the treatment of hypertrophic cardiomyopathy (HCM). HCM is a progressive disease in which the...
MyoKardia, Inc. (Nasdaq: MYOK) today announced that it has dosed the first subjects in a Phase 1 clinical study of MYK-224, a small molecule candidate being developed for the treatment of hypertrophic cardiomyopathy (HCM). HCM is a progressive disease in which the...
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it has randomized its first patient in a phase 2 clinical trial of AR201 for the treatment of egg allergy. AR201, an...
NKMax America, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer (NK) cell therapies, announced that it has treated the first subject in study SNK01-MX03, a phase I clinical trial evaluating...
Thought leaders from OmniComm Systems and Medable will discuss opportunities that will help clinical professionals become more successful in developing an overall strategy for designing and executing decentralized trials. The featured speakers will provide an overview...
Global clinical trial underway in 11 countries, including US, European, and Eastern European sites to evaluate safety, efficacy and tolerability of orally administered, gut-restricted LANCL2 agonist BT-11, in patients with ulcerative colitis – Landos Biopharma,...
Email
Text